Crosstalk between Gut and Brain in Alzheimer’s Disease: The Role of Gut Microbiota Modulation Strategies

1The human body hosts trillions of microorganisms, including bacteria, fungi, archaea, and viruses. These symbiotic microorganisms can be beneficial, neutral or detrimental to the host and play regulatory functions in both health and disease. They can be found in the urogenital organs, respiratory tract, skin surface, and gastrointestinal tract (GIT). About 95% of the symbiotic microorganisms of the human microbiome reside in the gut. Intricate ecological colonies of microorganisms dwell in the GIT and are collectively known as the gut microbiota (GM). The GM comprises mainly bacteria, fungi, bacteriophages, archaea, protozoa, and eukaryotic viruses and about 100 trillion microorganisms are harbored in the human GIT. Firmicutes, Bacteroides, Proteobacteria and Actinobacteria represent the major bacteria of the gut, followed by Bifidobacterium, Clostridium, Eubacterium, Peptococcus, Provetella, etc.. The small intestine consists of various types of bacteria, with content levels ranging from 104 bacteria/mL to 106–107 bacteria/mL at the ileocecal junction, while the large intestine contains most of the non-spore forming bacteria (from 1011–1012 bacteria/g content). The population of GM is different for each person and is composed of various bacterial species. Furthermore, the composition of the GM is different at different stages of life. In older age individuals, increased Firmicutes and Bacteroidetes populations can be observed as compared to in younger individuals. The GM is involved in metabolic processes and defense mechanisms and represents a dynamic and diverse population which impacts on the health and disease of the host. The GM develops the immune system in the intestinal mucosa and protects the host from carcinogens by releasing short-chain fatty acids (SCFA). Alterations of the GM community are referred to as dysbiosis, and these can lead to metabolic disorders. However, recent studies have proposed that this can also affect the central nervous system (CNS) because of the microbiota–gut–brain axis (MGBX). The brain regulates the secretory and sensory functions of the gut, and the connection between the gut and brain is interceded by physiological channels such as the autonomic nervous system, neuroendocrine system, neuroimmune pathways, and signaling molecules produced by the GM. However, the actual mechanism and relationship between neural dysfunction and gut dysbiosis is elusive. Emerging evidence suggests that gut dysbiosis can cause neurocognitive disorders such as schizophrenia, depression, bipolar disorder, anxiety, post-traumatic stress disorder, obsessive-compulsive disorder, and dementia, as well as the psychological and behavioral symptoms of dementia (Table 1). Additionally, metabolic syndromes and gut dysbiosis also contribute to Alzheimer’s disease (AD) and effect memory, learning, and hippocampal plasticity. Diet, probiotics, and other therapeutic strategies have positive effects on GM modulation that may be helpful in the treatment of AD, as these factors alter the composition of the GM and have a positive impact on the host, improving the health status of the gut and body overall. This review summarizes the role of GM dysbiosis, microbial metabolites, and metabolic impairment in AD. Additionally, the role of potential therapeutic strategies in modulating the GM composition and techniques to characterize the gut microbiome are also highlighted.

2During metabolic processes, the GM can produce several bioactive metabolites that can enter into the bloodstream via absorption into enterohepatic circulation. Metabolites linked to the phenotype of a disease can be recognized by nuclear magnetic resonance (NMR) and mass spectrometry-based metabolomics of body fluids such as urine, feces, or plasma. This makes it possible to carry out joint analyses of the host phenotypes, metabolome, and microbiome to identify mechanistic links. The GM metabolizes a plethora of neurotransmitters and neuromodulators (such as short-chain fatty acids (SCFA), gamma-aminobutyric acid, acetylcholine, dopamine, glutamate, and serotonin). Microbial species such as Saccharomyces, Bacillus, Lactobacillus, Escherichia, and Bifidobacterium are known to produce these types of neurotransmitters. Preliminary human studies have revealed that bacterial-based interventions can also change neurotransmitter levels involved in synaptic plasticity (including brain-derived neurotrophic factor), and regulate the activity of N-methyl-d-aspartate and serotonin receptors. Impairment of the GM composition or their metabolites modulates the gut–brain axis and regulates cognition, memory, mood, and social behavior. Moreover, dysbiosis may result in the formation of toxic misfolded proteins with a β-sheet conformation that promotes loss of synaptic connections, cellular cell dysfunction, and neurodegeneration. The pathways involved in MGBX are illustrated in Figure 1. Moreover, some of the major microbial metabolites (neurotransmitters) and their role in brain health are exhibited in Table 2.

3Dementia is a group of symptoms or a syndrome that causes deterioration in memory, behavior, thinking, ability to perform daily activities, judgement, and language. Dementia generally affects the elderly people but is not classified as a normal part of aging. Among different kinds of dementia, AD is the most common, and it contributes to 60–80% of dementia cases. It is one of the rapidly growing brain diseases and it has been reported that AD and other types of dementia represent the 5th most prominent reason for deaths around the globe. Around 50 million people suffer from dementia, and this is expected to double by 2030, and triple by 2050. Every year, approximately 10 million additional cases are reported worldwide. In the early stages of AD, people may suffer from memory lapses such as forgetting familiar locations and words, while the middle-stage is the longest stage that can last for years and the person may become angry or frustrated, confused, and act unpredictably. In the last stage, individuals lose the ability to carry on conversations, respond to their environment, and ultimately lose control of movement. As cognitive and memory conditions continue to be exacerbated, individuals require extensive care due to significant personality changes. Various immune-inflammatory variations have been found in patients with AD and mild cognitive impairment (MCI), including raised levels of pro-inflammatory cytokines and activated microglia that allow crosstalk between the peripheral and central immune systems. The major hallmarks of AD are as follows: development of amyloid beta (Aβ) plaques (Aβ peptides and Aβ-oligomers) and neurofibrillary tangles in the nerve cells; elevated generation of reactive oxygen species leads to neuroinflammation and cell death. Additionally, vascular abnormalities and mitochondrial damage also contribute to the pathogenesis of AD.

4The GM may contribute to metabolic health, but dysbiosis in GM composition triggers metabolic syndrome. Metabolic syndrome is a combination of abnormalities contributing to different diseases such as malnutrition, non-alcoholic liver disease, obesity, cardio-metabolic diseases and type-2 diabetes. Deficiency of SIRT3, known as a mitochondrial deacetylase, is a significant cause of metabolic syndrome. SIRT3 regulates the functioning of critical mitochondrial proteins by deacetylation. Tyagi et al. stated that deficiency of SIRT3 increases the formation of amyloid plaques and induces neuroinflammation in the brain. They crossed SIRT3−/− mice with APP/PSI mice (double-transgenic mouse models of AD expressing a chimeric mouse/human amyloid precursor protein and containing the L166P mutation, both directed to the CNS) and generated APP/PS1/SIRT3−/− mice with metabolic syndrome and amyloid pathology. Aggravation of glucose intolerance, insulin resistance, deposits of Aβ, and hallmarks of neuroinflammation such as tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and cyclooxygenase-2 were observed in the generated mice. Additionally, activated and proliferated microglial cells were also reported. Thus, hypothetically, metabolic syndrome and the induced amyloid pathology may interact with age related disorders such as diabetes, cardiovascular diseases, obesity, and hypertension and coexist with AD. Additionally, Gupta et al. revealed that type-2 diabetes mellitus contributes to the pathophysiology of AD. Thomas et al. agreed with this and stated that studied diabetic subjects (n = 69) suffered from at least 1 AD risk factor (e.g., cognitive decline, Aβ deposition, hyperphosphorylated tau, and genetic susceptibility). On the other hand, obesity is also associated with morphological and functional impairment in mitochondria that initiate insulin resistance (responsible for tau hyperphosphorylation and Aβ aggregation) peripheral inflammation, memory deficits, and oxidative stress that increase the risk of AD. Cuomo et al. disclosed that PCR and NMR analyses showed that Helicobacter pylori could potentially modulate AD, type-2 diabetes, cardio-metabolic disease, and obesity. Helicobacter pylori induces high levels of amino acids and activates the mammalian target of rapamycin complex 1 (regulates the host’s metabolism) and branched-chain amino acids. Furthermore, Helicobacter pylori toxin VacA resides within the mitochondria, contributing to the depletion of ATP, oxidative stress, and causes fragmentation of these organelles that induces autophagy and endure bacterial colonization of gastric mucosa. It also modulates the inflammation of hyperphosphorylation of tau proteins and stimulates Aβ formation.

5The GM has various links to inflammatory and metabolic pathways. Dysbiosis affects the synthesis of signaling proteins that influence metabolic processes related to AD progression. Aging alters the GM composition (high abundance of pro-inflammatory bacteria than anti-inflammatory bacteria) and induces local systematic inflammation that causes impairment in the permeability of the GIT and blood–brain barrier function. Peptostreptococcaceae, Clostridiaceae, Bifidobacteriaceae, Turicibacteraceae, Mogibacteriaceae, and Ruminococcaceae families were found to be less abundant as compared to Bacteroidaceae, Gemellaceae, and Rikenellaceae families in AD participants. More specifically, it has been stated that dysbiosis contributes to the enhancement of pro-inflammatory bacteria (such as Verrucomicrobia, Escerchia/Shigella, Proteobacteria, and Pseudomonas aeruginosa) and decreases the abundance of anti-inflammatory bacteria (such as Eubacterium hallii, Bacillus fragilis, Bacteroides fragilis, Eubacterium rectale, Faecalibacterium prausnitzii, and Bifidobacterium), potentially promoting neuroinflammation and worsening the formation of Aβ plaques. Decreases in microbial diversity have been reported in a microbiome study of AD and MCI human patients, with progressive growth of Enterobacteriaceae, Enterobacteriales, and Gammaproteobacteria being observed in comparison to controls. Moreover, enhanced biosynthesis and glycan metabolism, decreases in immune system-related pathways, and decreases the abundance of Ruminococcaceae, Lachnospiraceae, Firmicutes, and Clostridiaceae were also noted in patients. On the other hand, Lee et al. revealed that a transgenic murine model of AD showed significant changes in phyla (e.g., Bacteroidetes and Firmicutes), while an increase in Clostridium leptum group was also observed. Additionally, dysbiosis may promote AD symptoms, such as oxidative stress and insulin resistance. Hypothetically, it has been stated that the GM might modulate the oxidative state of the CNS through the produced metabolites. Suppressed levels of butyrate could enhance mitochondrial dysfunction resulting in the production of reactive oxygen species. Cerovic et al. stated that gut dysbiosis leads to both central and peripheral pathological events that could possibly increase the risk of AD. Dysbiosis in 5xFAD mice was associated with the progression of the CCAAT/enhancer binding protein β/asparagine endopeptidase pathway that mediated AD pathology through cleaving both Aβ precursor and Tau proteins. In a recent study, Li et al. used RNA sequencing, Y maze, transcriptome sequencing, Gene Expression Omnibus, and quantitative reverse-transcriptase PCR techniques for APPswe/PS1ΔE9 transgenic mice and wild-type mice to examine the role of dysbiosis in AD. They found a significantly different composition of GM, decreased cognitive ability, and increased amyloid formation. Microbiota-mediated intestinal and systemic immune aberrations trigger the pathogenesis of AD in ADLPAPT mice. Thus, it can be concluded that impairment of the GM is correlated with decreases in cognitive function and might play role in the enhancement of the amyloid deposition via stimulating the mitogen-activated protein kinase signaling pathways (these control a wide range of cellular processes, such as apoptosis, differentiation, proliferation, and stress responses) in the brain. Taken together, the possible role of gut dysbiosis in contributing to neurodegeneration and AD is illustrated in Figure 2.

6Amyloids are unique proteins with self-aggregation properties, and their accumulation can cause cellular dysfunction. Initiation of Aβ in the brain is elusive, however, different in vitro and in vivo studies have claimed that amyloids produced by GM may cross-seed Aβ deposition. Bacterial strains, such as Escherichia coli, Bacillus subtilis, Salmonella Typhimurium, Pseudomonas fluorescens, Staphylococcus aureus, etc., are considered to produce amyloids. These strains produce curli, TasA, CsgA, FapC, phenol soluble modulins, etc., amyloids that promote the misfolding of Aβ fibrils and oligomers. The production of amyloid proteins helps bacterial cells to bind to each other and form biofilms to resist destruction by immune or physical factors. It has been documented that bacterial amyloids are different from the amyloids in the brain in terms of their primary structure, but share similarities in their tertiary structure. Exposure to bacterial amyloid proteins in the gut may cause priming of the immune system that, in turn, increases the immune responses to the endogenous production of neural amyloids in the CNS. Bacterial amyloids, through molecular mimicry, may act as prion proteins that evoke cross-seeding in which the amyloidogenic protein causes the production of another protein, such as a host protein with a different primary structure, to adopt the pathogenic β-sheet structure. Osorio et al. proposed that amyloids are antigens that generate a defensive response to Aβ deposition in order to suppress danger signals. CsgA shares dissimilarity in sequences with Aβ42 but is similar in triggering AD-related pathogenic effects and promoting cerebral plaque deposition. In a recent study, Javed et al. claimed that FapCS favorably bound with Aβ, showed a catalytic capacity in seeding peptide amyloidosis, impaired cognitive performance, and behavior pathology in vitro, in silico and in a zebrafish AD model. Additionally, phenol soluble modulins contain cross-α structure and form cross-β fibrils associated with AD. Sampson et al. exhibited that curli-producing Escherichia coli, enhance the pathology of amyloid α-synuclein (involved in the progression of AD, dementia and Parkinson’s disease) in the gut and brain of mice. In a similar study, increased expression of Toll-like receptor 2, and pro-inflammatory mediators IL-6 and TNF, in association with astrogliosis and microgliosis, were also observed in rats exposed to the curli amyloid. Cattaneo et al. stated that amyloidosis positive patients exhibited higher serum levels of IL-1β, IL-6, C-X-C motif chemokine ligand, and nod-like receptor protein 3, and lower serum levels of anti-inflammatory cytokine IL-10.

7Lipopolysaccharides (LPS) mainly produced by Gram-negative bacteria (Proteobacteria and Bacteroidetes: pro-inflammatory bacteria) can induce inflammation and disrupt the blood–brain barrier function. A plethora of in vivo and in vitro studies suggested that LPS activate several intracellular molecules that change the expression of different inflammatory mediators and in turn, contribute or initiate the progression/development of neurodegeneration. Khan et al. stated that LPS activate the Toll-like receptor 4 and cause the epithelial and intestinal-wall inflammation that results in leaky gut. LPS also activate astrocyte and microglial cells in the GIT that secrete pro-inflammatory cytokines, those later gain entry to the bloodstream through leaky gut. This serum LPS cause disruption in the blood–brain barrier and may enter the brain and reactivate microglia, and astrocytes, and various amyloid genic and inflammatory pathways. Increased inflammatory cytokines and nuclear factor kappa B (NF-κB) leads to an increase in amyloid precursor protein and Aβ protein cleavage and accumulation that causes the death of neurons and AD development. Moreover, LPS promote Aβ42 fibrillogenesis which triggers the formation of Aβ1–40/42 plaques in the white and grey matter of AD brains. The abundance of LPS was also observed in the hippocampus and in the neocortex, and in the lysates from the superior temporal lobe of AD brains. A study suggested that LPS treatment in mice contributed to neuroinflammation, cognitive impairment and sickness behavior with neuronal loss in the hippocampus and activated microglia. The levels of IL-1β, TNF-α, nitric oxide, and prostaglandin E2 were increased with the activation of the NF-κB signaling pathway. Thingore et al. reported that LPS administration enhanced neuroinflammation and contributed to oxidative stress through a decrease in reduced glutathione, superoxide dismutase, and increases in lipid peroxidation in the brains of mice. Treatment with 2,4,6-trinitrobenzenesulfonic acid in mice caused colitis and increased membrane permeability, levels of LPS, Enterobacteriaceae (including Escherichia coli) with a decrease in Lactobacillus johnsonii in the GM composition, activated NF-κB and TNF-α, and displayed cognitive impairment. On the other hand, treatment with Lactobacillus johnsonii restored the GM dysbiosis, levels of LPS in the blood, memory and cognitive impairment. Thus, bacterial LPS and amyloids contribute to the hallmarks of AD through MGBX and restoration of GM homeostasis could be beneficial for treating AD.

8Different epidemiological studies suggest a strong correlation among lifestyle-related factors, diet, and the onset and consolidation of AD and other kinds of dementia. Studies have reported that nutritional interventions might be helpful to mitigate or delay the risk of cognitive impairment, AD and other non-psychiatric comorbidities. Fieldhouse et al. stated that a suboptimal diet is related to severely impaired cognition, attributed to low vegetable consumption and is pronounced in AD and dementia. Intake of a diet rich in probiotics, plant-based foods, polyphenols, vitamins, antioxidants, and ω-3 polyunsaturated fatty acids can delay AD, as diet can shape host-associated GM composition. Additionally, low intake of saturated fats, refined sugars, and animal-derived proteins is also considered beneficial in this regard. Moreover, healthy dietary patterns can be beneficial for cognitive health and can show neuroprotective properties. The Mediterranean diet is deemed beneficial for AD patients as it is rich in many components such as legumes, fruits, vegetables, cereals, polyphenols, non-digestible carbohydrates, and unsaturated fatty acids. Polyphenols (PPs) are naturally occurring bioactive compounds and the most abundant forms of antioxidants in the human diet. PPs have been recognized as potent agents that can lower the risk of AD. Furthermore, vitamins have a positive effect on AD due to their role in preventing oxidative stress and inflammation that would otherwise lead to Aβ and tau phosphorylation. The gut microbiome can produce vitamins that are necessary for brain health (including vitamin B6, B9, B12, etc.). Park et al. exhibited that deficiencies of folate and vitamin B12 are associated with impaired memory function and hippocampal insulin signaling in AD rats. Thus, supplementation of vitamins (such as vitamin B complex) may also be helpful in delineating a treatment of AD. Prebiotics promote the growth of beneficial bacteria (including lactobacillus and bifidobacteria), and improve dysbiosis and the associated inflammatory conditions that may ameliorate cognitive impairment. Conversely, the Western diet, consisting of saturated and high trans-fat, high sugar with fewer vegetables and fruits is considered a nutrient-imbalanced diet pattern. This diet may cause metabolic syndromes and diseases and can increase the chances of AD development. A recent study by Gabriel et al. stated that chronic exposure of a high-fat, high-sugar Western diet to C57BL/6N mice significantly contributed to obesity and memory impairment. These dietary patterns increase the abundance of Flavobacterium, Runella, and Flectobacillus that can activate inflammatory responses by regulating IL-1β and the NF-κB pathways. Ye et al. reported that diets with high-fat can affect the gut–brain axis in zebrafish and that this could be due to modulation of the GM. For example, the abundance of Acinetobacter is <0.1% of the total GM in normal conditions and it is associated with inflammatory responses in the gut. However, diets with high-fat content can enhance its abundance by 100-fold, which may lead to LPS production and neuroinflammation.

9On the other hand, melatonin (a hormone produced by the pineal gland) can prevent or slow down the progression of AD. Melatonin has the potential to enhance Aβ clearance through glymphatic-lymphatic drainage, blood–brain barrier transportation and degradation pathways, and ameliorates Aβ-induced neurotoxicity. It has been stated that melatonin controls the GM, and its treatment can increase the ratio of Firmicutes to Bacteroidetes and Akkermania and decrease the pathogenic bacteria in gut. Melatonin levels were observed to be lower in AD subjects as compared to healthy aged subjects. Thus, supplementation of melatonin can exert neuroprotective effects on the brain. Additionally, administration of melatonin can reduce Aβ plaques and enhance cognitive performance. The role of diet and other food components in AD is demonstrated in Table 3.

10Probiotics are microorganisms present in the human gut and when supplied in adequate quantities confer health benefits to the host. Diet-based interventions include administration of probiotics through specific supplements, supplementation with PPs, probiotic enriched foods, consumption of dietary fiber, and foods rich in prebiotics. Probiotics can secrete and produce bacterio-toxins (such as bacteriocins) which can suppress bacterial invasion and block pathogen adhesion to epithelial cells. Probiotics compete with pathogenic bacteria for nutrients and binding sites. Additionally, they increase the integrity of the barrier and mucus production by exerting a trophic effect on intestinal mucosa and effects on epithelial cell cytokine secretion. Oral bacteriotherapy with probiotics has been recently identified to treat and prevent many pathologies. A systematic review suggested that preliminary animal studies support the potential role of probiotics in improving cognitive functioning, possibly by decreasing the levels of oxidative and inflammatory biomarkers in MCI or AD; Lactobacillus and Bifidobacterium strains could be the most promising candidates (Table 4). Additionally, the effectiveness of probiotics administration could be affected by dosage, the proportion of each strain, severity of patients and so forth.

11Fecal microbiota transplantation (FMT) is being studied as a potential intervention for many conditions. FMT is the process of transferring prescreened stool into the GIT of patients to restore the function and increase the overall diversity of GM. Fecal material is expected to be from a highly organized stool bank and administrated through colonoscopy, enema, or capsule. At present, FMT is widely accepted for the treatment of Clostridium difficile infections, however, trials related to human diseases such as cancer, neurodegenerative diseases, and inflammatory bowel disease to metabolic diseases are still ongoing worldwide. FMT could be beneficial for cognitive impairment and decreasing Aβ plaques in AD animals’ brains. However, studies suggest that caution should be taken in the premature extrapolation of data from preclinical studies because of the inherent limitations of rodent models. Standardization, stool bank services and management, safety assessment, etc., have still not been significantly upgraded, causing complex challenges for regulators and clinicians. Stool availability, adverse effects, and poorly or undefined mechanisms of action are the major concerns related to FMT. Additionally, Sood et al. documented that FMT safety with other routes of administration, patient acceptance, and tolerability must be assessed before recommending this method as the most appropriate way to administer FMT (Table 4).

12Several techniques are currently being used to understand the role of GM in both inducing and preventing specific pathological conditions. The 16S rRNA sequencing method represents the mainstay in terms of a regular and standardized approach to evaluating the composition of human microbiome taxa species down to the genus level. However, next-generation sequencing technologies such as Ion Torrent, Illumina sequencing, and Roche 454 pyrosequencing can identify species composition using shorter DNA stretches with a higher sequence coverage. Computational approaches to identify the 16S rRNA sequencing of disease or non-disease causing microbes have also been developed to better evaluate the biology of the GM community. On the other hand, using 16S rRNA sequencing makes it challenging to understand the genomic information of species with low abundance. Thus, recent studies have been shifting towards the use of high-throughput data techniques for obtaining quantitative and qualitative information of metabolites, DNA, mRNA transcripts, and proteins of the microbial groups in the microbiome. Shotgun metagenomic sequencing helps analyze the whole genomic DNA of bacteria to understand and identify the functional potential of microbial genes. Additionally, meta-omic approaches can be helpful in providing a comprehensive functional view of microorganisms and their role within the microbiome. The HMP Unified Metabolic Analysis Network is another example that can perform functional and metabolic reconstructions of metagenomic data. Although high-throughput next-generation sequencing methods are advantageous, they are also expensive and complex.

13Most of the animal studies cite here, explored the possible interaction between GM composition and cognitive function. However, human studies were performed on subjects with an established diagnosis of dementia, and outside the geriatric constructs of MCI and cognitive frailty. Thus, a substantial gap exists between the interventional and observational studies performed in animal models of AD. Additionally most of the clinical studies have been conducted with small samples, which is why comprehensive profiling of GM composition and functionality is lacking. Longitudinal studies of high-risk populations are required to examine temporal changes in the GM, as direction of causality cannot be based via cross-sectional studies. Implementation of neuroimaging variables and blood biomarkers as secondary outcomes can enable us to better understand the GM and cognitive functioning.

14GM metabolites may affect the host cellular pathways involved in differentiation, maturation, and proliferation functions. Well-defined methodological standards are needed to compare the studies, and other variables such as drugs, concomitant pathologies, and diet must be carefully considered in analyses. Many studies related to uncovering the role of the GM in AD are limited by the fact that only the 16S rRNA sequencing method is being used, providing data on taxa down to the genus level. Because of this, important associations at the strain or species level may be lost. Identifying and characterizing the role of specific microbiomes should be a primary focus of MGBX research. The use of high-throughput next generation sequencing methods for metagenomics, metabolomics, and informatics will be helpful in managing the databases deriving from ongoing GM studies. However, successful results depend on the treatment, disease stage, proper combination of nutrients and bacterial strains. Diet, probiotics and FMT are considered to represent potential therapeutics for AD, MCI, and other neurodegenerative diseases. However, there are still limitations, especially in probiotic and FMT interventions. Cox et al. stated that caloric restriction experiments exhibited that Lactobacillus and Faecalibaculum genera protected mice from the development of Aβ plaques, while the Lachnospiraceae family and Bacteroides genus were associated with higher Aβ levels in the brain. However, these findings are only apparent in female mice, not male mice; thus, further studies are needed to explore this issue. Other factors such as sex may significantly impact GM links to neurodegeneration. Halverson et al. concluded that not all studies have shown effective therapeutic responses because studies have used different treatment methods, study conditions, times of treatments, dosages, and probiotic strains. Therefore, research is needed to better understand the underlying mechanisms, specific procedures, and guidelines to enhance the effectiveness of GM modulation.

15Evolving evidence from animal and human studies suggests that dysbiosis affects the GIT and its related diseases and can also contribute to neurodegeneration due to the fact that the gut communicates with the brain through the gut–brain axis. The GM can produce neurotransmitters that can influence the relations hip between the neurochemistry of the brain and brain disorders such as mood, cognition, behavior, etc. Interestingly, the fungal taxa of the GM with gut bacteria also correlates with AD markers. Diet, probiotics, and FMT administration can modulate the GM composition, alleviating the pathological changes associated with AD. From the safety point of view, diet is one of the most suitable interventions to modulate dysbiosis, but more research is required in this area before application in clinical practice. Thus, further studies are required to understand the specific effects of these therapeutics in the prevention or alleviation of AD.